» Articles » PMID: 38144411

Timing of Elimination of Hepatitis C Virus in Canada's Provinces

Overview
Journal Can Liver J
Specialty Gastroenterology
Date 2023 Dec 25
PMID 38144411
Authors
Affiliations
Soon will be listed here.
Abstract

Infection with chronic hepatitis C virus is a global public health concern. A recent study concluded that Canada is on track to achieve hepatitis C elimination goals set by the World Health Organization if treatment levels are maintained. However, recently a falling temporal trend in treatments in Canada was observed, with most provinces seeing a decrease before the global coronavirus pandemic. This study assesses the timing of elimination of hepatitis C in the 10 provinces of Canada. Previously published disease and economic burden model of hepatitis C infection was populated with the latest epidemiological and cost data for each Canadian province. Five scenarios were modelled: maintaining the status quo, decreasing diagnosis and treatment levels by 10% annually, decreasing diagnosis and treatment levels by 20% annually, increasing them by 10% annually, and assuming a scenario with no post-coronavirus pandemic recovery in treatment levels. Year of achieving hepatitis C elimination, necessary annual treatments for elimination, and associated disease and economic burden were determined for each province. If status quo is maintained, Manitoba, Ontario, and Québec are off track to achieve hepatitis C elimination by 2030 and would require 540, 7,700, and 2,800 annual treatments, respectively, to get on track. Timely elimination would save 170 lives and CAD $122.6 million in direct medical costs in these three provinces. Three of Canada's provinces-two of them the most populous in the country-are off track to achieve the hepatitis C elimination goal. Building frameworks and innovative approaches to prevention, testing, and treatment will be necessary to achieve this goal.

Citing Articles

Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.

Torre P, Festa M, Sarcina T, Masarone M, Persico M Viruses. 2024; 16(11).

PMID: 39599906 PMC: 11598908. DOI: 10.3390/v16111792.


Hepatitis C Diagnosis and Treatment Among Indigenous People in a Canadian Context: Challenges and Community-Led Solutions.

Dunn K, Biondi M, Lee S Microorganisms. 2024; 12(11).

PMID: 39597752 PMC: 11596142. DOI: 10.3390/microorganisms12112364.


Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada.

Sahakyan Y, Erman A, Wong W, Greenaway C, Janjua N, Kwong J Viruses. 2024; 16(8).

PMID: 39205198 PMC: 11359558. DOI: 10.3390/v16081224.


Impact of the COVID-19 pandemic on hepatitis C virus screening in provincial prisons in Montreal, Quebec, Canada.

Kronfli N, Leone F, Dussault C, Miliani G, Gallant E, Potter M Front Public Health. 2024; 12:1380126.

PMID: 39109158 PMC: 11302355. DOI: 10.3389/fpubh.2024.1380126.


Impact of the COVID-19 Pandemic on Hepatitis C Treatment Initiation in British Columbia, Canada: An Interrupted Time Series Study.

Morrow R, Binka M, Li J, Irvine M, Bartlett S, Wong S Viruses. 2024; 16(5).

PMID: 38793537 PMC: 11125629. DOI: 10.3390/v16050655.


References
1.
Stone J, Martin N, Hickman M, Hutchinson S, Aspinall E, Taylor A . Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017; 112(7):1302-1314. PMC: 5461206. DOI: 10.1111/add.13783. View

2.
Hamadeh A, Haines A, Feng Z, Thein H, Janjua N, Krahn M . Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat. 2020; 27(12):1419-1429. DOI: 10.1111/jvh.13373. View

3.
. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3):161-176. DOI: 10.1016/S2468-1253(16)30181-9. View

4.
Won Y, Kang K, Sanchez Gonzalez Y, Razavi H, Dugan E, Han K . A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. PLoS One. 2020; 15(4):e0232186. PMC: 7188208. DOI: 10.1371/journal.pone.0232186. View

5.
Jacka B, Larney S, Degenhardt L, Janjua N, Hoj S, Krajden M . Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. Am J Public Health. 2019; 110(1):45-50. PMC: 6893337. DOI: 10.2105/AJPH.2019.305379. View